Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every 8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruit, W. H., Punt, C. J., Goey, S. H., de Mulder, P. H., Gratama, J. W., Eggermont, A. M., Bolhuis, R. L., Stoter, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074736/
https://www.ncbi.nlm.nih.gov/pubmed/8826864
_version_ 1782138031758639104
author Kruit, W. H.
Punt, C. J.
Goey, S. H.
de Mulder, P. H.
Gratama, J. W.
Eggermont, A. M.
Bolhuis, R. L.
Stoter, G.
author_facet Kruit, W. H.
Punt, C. J.
Goey, S. H.
de Mulder, P. H.
Gratama, J. W.
Eggermont, A. M.
Bolhuis, R. L.
Stoter, G.
author_sort Kruit, W. H.
collection PubMed
description Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every 8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a high response rate of 41% (CI 18-67%), but was accompanied by severe cardiotoxicity (41%) and central nervous system toxicity (28%). The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of 20% (CI 7-43%).
format Text
id pubmed-2074736
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20747362009-09-10 Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. Kruit, W. H. Punt, C. J. Goey, S. H. de Mulder, P. H. Gratama, J. W. Eggermont, A. M. Bolhuis, R. L. Stoter, G. Br J Cancer Research Article Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every 8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a high response rate of 41% (CI 18-67%), but was accompanied by severe cardiotoxicity (41%) and central nervous system toxicity (28%). The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of 20% (CI 7-43%). Nature Publishing Group 1996-09 /pmc/articles/PMC2074736/ /pubmed/8826864 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Kruit, W. H.
Punt, C. J.
Goey, S. H.
de Mulder, P. H.
Gratama, J. W.
Eggermont, A. M.
Bolhuis, R. L.
Stoter, G.
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
title Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
title_full Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
title_fullStr Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
title_full_unstemmed Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
title_short Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
title_sort dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074736/
https://www.ncbi.nlm.nih.gov/pubmed/8826864
work_keys_str_mv AT kruitwh doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma
AT puntcj doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma
AT goeysh doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma
AT demulderph doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma
AT gratamajw doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma
AT eggermontam doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma
AT bolhuisrl doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma
AT stoterg doseefficacystudyoftwoschedulesofhighdosebolusadministrationofinterleukin2andinterferonalphainmetastaticmelanoma

Ejemplares similares